Publicacións (15) Publicacións de Paula Guijarro Sanchez

2024

  1. Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions

    International Journal of Antimicrobial Agents, Vol. 63, Núm. 5

  2. Epidemiology, resistance genomics and susceptibility of Acinetobacter species: results from the 2020 Spanish nationwide surveillance study

    Eurosurveillance, Vol. 29, Núm. 15

2023

  1. Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain

    International Journal of Antimicrobial Agents, Vol. 61, Núm. 4

  2. Antimicrobial Activity of Cefiderocol against the Carbapenemase-Producing Enterobacter cloacae Complex and Characterization of Reduced Susceptibility Associated with Metallo-β-Lactamase VIM-1

    Antimicrobial agents and chemotherapy, Vol. 67, Núm. 5, pp. e0150522

  3. In vitro development of imipenem/relebactam resistance in KPC-producing Klebsiella pneumoniae involves multiple mutations including OmpK36 disruption and KPC modification

    International Journal of Antimicrobial Agents, Vol. 62, Núm. 4

  4. Interplay between OXA-10 β-Lactamase Production and Low Outer-Membrane Permeability in Carbapenem Resistance in Enterobacterales

    Antibiotics, Vol. 12, Núm. 6

  5. Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 5, pp. 1195-1200

2022

  1. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 10, pp. 2809-2815

  2. Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing Enterobacterales

    Antimicrobial Agents and Chemotherapy, Vol. 66, Núm. 2

  3. Carbapenem Resistance in Acinetobacter nosocomialis and Acinetobacter junii Conferred by Acquisition of blaOXA-24/40 and Genetic Characterization of the Transmission Mechanism between Acinetobacter Genomic Species

    Microbiology Spectrum, Vol. 10, Núm. 1

  4. Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencing

    International Journal of Antimicrobial Agents, Vol. 59, Núm. 1

  5. Reply to Shapiro, "Cefepime/Enmetazobactam Is a Clinically Effective Combination Targeting Extended-Spectrum b-Lactamase-Producing Enterobacterales"

    Antimicrobial Agents and Chemotherapy

  6. Selection of AmpC β-Lactamase Variants and Metalloβ- Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/ XDR Pseudomonas aeruginosa Infections

    Antimicrobial Agents and Chemotherapy, Vol. 66, Núm. 2

2021

  1. Activity of imipenem, meropenem, cefepime, and sulbactam in combination with the β-lactamase inhibitor ln-1-255 against acinetobacter spp.

    Antibiotics, Vol. 10, Núm. 2, pp. 1-15

  2. Occurrence of the p019 Gene in the blaKPC-Harboring Plasmids: Adverse Clinical Impact for Direct Tracking of KPC-Producing Klebsiella pneumoniae by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry

    Journal of clinical microbiology, Vol. 59, Núm. 8, pp. e0023821